1. Home
  2. CE vs LEGN Comparison

CE vs LEGN Comparison

Compare CE & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Celanese Corporation

CE

Celanese Corporation

SELL

Current Price

$48.70

Market Cap

5.5B

Sector

Industrials

ML Signal

SELL

Logo Legend Biotech Corporation

LEGN

Legend Biotech Corporation

HOLD

Current Price

$16.11

Market Cap

4.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CE
LEGN
Founded
1918
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.5B
4.6B
IPO Year
2004
2020

Fundamental Metrics

Financial Performance
Metric
CE
LEGN
Price
$48.70
$16.11
Analyst Decision
Buy
Buy
Analyst Count
18
14
Target Price
★ $63.39
$40.93
AVG Volume (30 Days)
1.4M
★ 2.4M
Earning Date
11-02-2026
11-10-2026
Dividend Yield
★ 0.25%
N/A
EPS Growth
★ 23.62
N/A
EPS
★ 2.21
N/A
Revenue
★ $9,544,000,000.00
N/A
Revenue This Year
$4.47
$38.78
Revenue Next Year
N/A
$17.61
P/E Ratio
$22.16
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$35.39
$15.97
52 Week High
$70.70
$37.50

Technical Indicators

Market Signals
Indicator
CE
LEGN
Relative Strength Index (RSI) 49.61 34.08
Support Level $43.28 N/A
Resistance Level $49.63 $19.92
Average True Range (ATR) 2.19 1.40
MACD -0.06 -0.75
Stochastic Oscillator 33.90 4.27

Price Performance

Historical Comparison
CE
LEGN

About CE Celanese Corporation

Celanese is a global specialty chemicals manufacturer. It operates in two segments: acetyl chain, and engineered materials. Acetyl chain profitability is exposed to commodity-linked raw materials and product pricing spreads. Engineered materials converts basic chemicals into higher-margin specialty polymers and compounds engineered for specific customer applications in automotive, medical, electronics, and industrial end markets.

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

Share on Social Networks: